Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 1057-1064

  Fabre, Claire ^a   Gobbi, Marco ^b   Ezzili, Cyrine ^a   Zoubir, Mustapha ^a   Sablin, Marie Paule ^a   Small, Karen ^c   Im, Ellie ^c   Shinwari, Nabeegha ^c   Zhang, Da ^c   Zhou, Honghong ^c   Le Tourneau, Christophe ^a,d  

^a INSTITUT CURIE   (France)

^b UNIVERSITY OF GENOA   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

^d INSERM U900   (France)

Author keywords

Chronic lymphocytic leukemia; Cyclin dependent kinase; Dinaciclib; Relapsed refractory patients; Rituximab

Indexed keywords

BENDAMUSTINE; CREATININE; DINACICLIB; FLUDARABINE; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; FUSED HETEROCYCLIC RINGS; MONOCLONAL ANTIBODY; PYRIDINIUM DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; KIDNEY FAILURE; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR LYSIS SYNDROME; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASTHENIA; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIN-DEPENDENT KINASES; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRIDINIUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84919736439     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2583-9     Document Type: Article

References (38)

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer M et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164-1174
2. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088
3. Tam CS, O'Brien S, Weirda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980
4. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:3016-3024
5. Cuthill K, Devereux S (2013) How I treat patients with relapsed chronic lymphocytic leukaemia. Br J Haematol 163:423-435
6. Cortelezzi AM, Sciume M, Liberati AM, Vincenti D, Cuneo A, Laurenti L et al (2014) Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia 28:642-648
7. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Farrajoli A (2013) Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31:584-591
8. Rodriguez-Vicente AE, Diaz MG, Hernandez-Rivas JM (2013) Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet 206:49-62
9. Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou YM, Statkevich P, Yao SL, Bannerji R (2013) A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 11:259
10. Parry D, Guzi T, Shanahan F, Davis N, Prabjavalkar D, Wiswell D et al (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9:2344-2353
11. Blachly JS, Byrd JC (2013) Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma 54:2133-2143
12. Bose P, Simmons GL, Grant S (2013) Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 22:723-738
13. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153-166
14. Morgan DO (1995) Principles of CDK regulation. Nature 374:131-134
15. Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8(4 Suppl):S32-S37
16. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783
17. Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140:3079-3093
18. Gallorini M, Cataldi A, di Giacomo V (2012) Cyclin-dependent kinase modulators and cancer therapy. BioDrugs 26:377-391
19. Canavese M, Santo L, Raje N (2012) Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther 13:451-457
20. Johnson AJ, Smith LL, Wagner AJ, Hessler J, Flynn JM, Jones JA, Zhang X et al (2010) Dinaciclib (SCH727965) is a novel cyclin dependent kinase inhibitor that promotes selective apoptosis in CLL cells and abrogates the protective effects of microenvironment cytokines. Presented at the 53rd ASH annual meeting and exposition, 10-13, December 2011, San Diego, CA, Abstract 971
21. Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, Altiok S, Pledger WJ (2011) The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 10:1018-1027
22. Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J et al (2013) The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS ONE 8:e59588
23. Abdullah C, Wang X, Becker D (2011) Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 10:977-988
24. Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ (2013) Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis 4:e566
25. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z et al (2011) Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 12:598-609
26. Robak T (2012) Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 12:503-515
27. Lepretre S, Jager U, Janssens A, Leblond V, Nikitin E, Robak T, Wendtner CM (2012) The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leuk Lymphoma 53:820-829
28. Griffin MM, Morley N (2013) Rituximab in the treatment of non-Hodgkin's lymphoma - a critical evaluation of randomized controlled trials. Expert Opin Biol Ther 13:803-811
29. Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115-123
30. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99:1038-1043
31. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC (2007) Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 13:2144-2150
32. Burger K, Muhl B, Rohrmoser M, Coordes B, Heidemann M, Kellner M et al (2013) Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA. J Biol Chem 288:21173-21183
33. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, et al (2010) Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration. Presented at the 53rd ASH annual meeting and exposition, 10-13, December 2011, San Diego, CA, Abstract 1396
34. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, et al (2011) Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. Presented at the 2011 ASCO annual meeting, 3-7, June 2011, Chicago, IL, Abstract 6623
35. Baiocchi RA, Flynn JM, Jones JA, Blum KA, Hofmeister CC, Poon J, et al (2010) Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients. Presented at the 53rd ASH annual meeting and exposition, 10-13, December 2011, San Diego, CA, Abstract 3966
36. Flynn JM, Andritsos LA, Jones JA, Johnson AJ, Maddocks K, Wiley E, et al (2013) Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Presented at the 55th ASH annual meeting and exposition, 7-10, December 2013, New Orleans, LA, Abstract 871
37. Sadowska M, Muvarak N, Lapidus RG, Sausville EA, Bannerji R, Gojo I (2010) Single agent activity of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in acute myeloid and lymphoid leukemia cells. Presented at the 53rd ASH annual meeting and exposition, 10-13, December 2011, San Diego, CA, Abstract 3981
38. Mita MM, Mita AC, Moseley J, Poon J, Small KA, Jou Y, et al (2011) A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: final results. Presented at the 2011 ASCO annual meeting, 3-7, June 2011, Chicago, IL, Abstract 3080